Action of an extract from the seeds of Fraxinus excelsior L. on metabolic disorders in hypertensive and obese animal models

• Published in: Food & function 2014-04, Vol.5 (4), p.786-796
• Main Authors: Montó, Fermí, Arce, Cristina, Noguera, Maria Antonia, Ivorra, Maria Dolores, Flanagan, John, Roller, Marc, Issaly, Nicolas, D'Ocon, Pilar
• Format: Article
• Language: English
• Subjects: Animals; Blood Glucose - metabolism; Blood Pressure - drug effects; Disease Models, Animal; Fraxinus - chemistry; Humans; Hypertension - drug therapy; Hypertension - metabolism; Hypertension - physiopathology; Hypoglycemic Agents - administration & dosage; Insulin - blood; Male; Obesity - drug therapy; Obesity - metabolism; Plant Extracts - administration & dosage; Rats; Rats, Inbred SHR; Rats, Zucker; Seeds - chemistry
• ISSN: 2042-6496; 2042-650X
• DOI: 10.1039/c3fo60539f

Nuzhenide and GI3, the principal secoiridoids of an extract obtained from the seeds of Fraxinus excelsior L. (FXE), are believed to be the active compounds responsible for the previously reported hypoglycemic effects of this extract. In this study, the effects of FXE were studied in two animal models which are representative of metabolic disorders: spontaneously hypertensive rats (SHR) and obese Zucker rats. SHR were acutely treated (oral gavage) with different doses of FXE. In addition, SHR and Zucker rats were chronically fed (20 or 5 weeks, respectively) with standard chow supplemented with FXE. Acute treatment with FXE (200 mg per kg body weight) decreased systolic blood pressure as in the case with captopril (50 mg per kg body weight). Chronic treatment with FXE at 100 mg per kg body weight per day, a dose equivalent to that showing hypoglycemic activity in humans, resulted in a significant decrease in glycemia (−16.3%), triglyceridemia (−33.4%) and body weight (−8.1%) in Zucker rats as well as a significant decrease in SBP in SHR (−6.7%), with a concomitant improvement in endothelial function in both strains. The broad-ranging effects of FXE may be due to a unique compositional profile that could be useful to prevent the metabolic syndrome, characterized by obesity, insulin resistance, glucose intolerance, hypertriglyceridemia and elevated blood pressure. Chronic treatment with FXE resulted in a significant decrease in glycemia, triglyceridemia and body weight in Zucker rats and a significant decrease in SBP in SHR, with a concomitant improvement in endothelial function in both strains.